Skip to main content
. 2014 Oct 3;29(1):80–87. doi: 10.1038/eye.2014.233

Table 3. Comparison of baseline with month 12 outcomes for 0.5 vs 2.0 mg dose of ranibizumab by two-way ANOVA (N=36).

Outcome variable Dose (mg) Baseline mean (SD) Month 12 mean (SD) P-value between regimens P-value within regimen
PED height, μm 0.5 402.96 (168.10) 235.36 (153.82) 0.95 <0.001
  2.0 438.30 (183.84) 193.24 (154.52)    
Central 1-mm thickness, μm 0.5 311.00 (96.68) 200.38 (48.70) 0.70 <0.001
  2.0 304.61 (77.78) 221.52 (60.41)    
PED SA (mm2) 0.5 10.98 (3.12) 7.94 (5.00) 0.35 <0.001
  2.0 10.10 (7.29) 5.53 (4.48)    
PED GLD, μm 0.5 4256.83 (445.18) 3541.71 (1061.11) 0.22 <0.001
  2.0 3982.64 (1431.51) 2875.82 (1456.70)    
CNV SA (mm2) 0.5 4.08 (3.86) 2.32 (2.91) 0.06 0.001
  2.0 1.65 (1.67) 0.70 (0.46)    
CNV GLD, μm 0.5 2599.32 (1468.19) 1811.08 (1367.71) 0.11 0.044
  2.0 1581.76 (775.25) 1350.51 (1011.17)    
Contrast sensitivity 0.5 25.73 (4.50) 25.18 (9.79) 0.54 0.75
  2.0 26.38 (6.5) 27.57 (7.09)    
BCVA LogMar 0.5 0.64 (0.21) 0.53 (0.44) 0.10 0.05
  2.0 0.52 (0.15) 0.41 (0.29)    

Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; GLD, greatest linear diameter; LogMar, logarithm10 reciprocal of snellen visual acuity equivalent; PED, pigment epithelial detachment; SA, surface area; SD, standard deviation.